NASDAQ:ANIP - ANI Pharmaceuticals Inc Common Stock Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$61.68 -2.15 (-3.37 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$61.68
Today's Range$61.3150 - $63.84
52-Week Range$42.23 - $74.70
Volume94,387 shs
Average Volume113,215 shs
Market Capitalization$760.02 million
P/E Ratio17.09
Dividend YieldN/A
Beta2.93

About ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP)

ANI Pharmaceuticals Inc Common Stock logoANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANIP
CUSIPN/A
Phone218-634-3500

Debt

Debt-to-Equity Ratio1.11
Current Ratio3.62
Quick Ratio2.75

Price-To-Earnings

Trailing P/E Ratio17.09
Forward P/E Ratio11.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$176.84 million
Price / Sales4.12
Cash Flow$5.7270 per share
Price / Cash10.77
Book Value$14.99 per share
Price / Book4.11

Profitability

EPS (Most Recent Fiscal Year)$3.61
Net Income$-1,070,000.00
Net Margins0.01%
Return on Equity27.16%
Return on Assets12.43%

Miscellaneous

Employees173
Outstanding Shares11,800,000

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Frequently Asked Questions

What is ANI Pharmaceuticals Inc Common Stock's stock symbol?

ANI Pharmaceuticals Inc Common Stock trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals Inc Common Stock's earnings last quarter?

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) issued its quarterly earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported $1.32 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.04. The specialty pharmaceutical company had revenue of $46.48 million for the quarter, compared to analysts' expectations of $49.93 million. ANI Pharmaceuticals Inc Common Stock had a return on equity of 27.16% and a net margin of 0.01%. The business's revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.74 EPS. View ANI Pharmaceuticals Inc Common Stock's Earnings History.

What guidance has ANI Pharmaceuticals Inc Common Stock issued on next quarter's earnings?

ANI Pharmaceuticals Inc Common Stock updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $5.43-6.08 for the period, compared to the Thomson Reuters consensus estimate of $5.55. The company issued revenue guidance of $212-228 million, compared to the consensus revenue estimate of $215.67 million.

What price target have analysts set for ANIP?

2 Wall Street analysts have issued 1 year target prices for ANI Pharmaceuticals Inc Common Stock's shares. Their predictions range from $80.00 to $82.00. On average, they anticipate ANI Pharmaceuticals Inc Common Stock's stock price to reach $81.00 in the next twelve months. View Analyst Ratings for ANI Pharmaceuticals Inc Common Stock.

What are Wall Street analysts saying about ANI Pharmaceuticals Inc Common Stock stock?

Here are some recent quotes from research analysts about ANI Pharmaceuticals Inc Common Stock stock:
  • 1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (5/14/2018)
  • 2. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)

Who are some of ANI Pharmaceuticals Inc Common Stock's key competitors?

Who are ANI Pharmaceuticals Inc Common Stock's key executives?

ANI Pharmaceuticals Inc Common Stock's management team includes the folowing people:
  • Mr. Arthur S. Przybyl, Chief Exec. Officer, Pres and Director (Age 61)
  • Mr. Stephen P. Carey, Chief Financial Officer and VP of Fin. (Age 47)
  • Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 55)
  • Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 46)
  • Dr. David J. Sullivan Ph.D., VP of Quality Operations

Has ANI Pharmaceuticals Inc Common Stock been receiving favorable news coverage?

Press coverage about ANIP stock has been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ANI Pharmaceuticals Inc Common Stock earned a news sentiment score of -0.01 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 46.32 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are ANI Pharmaceuticals Inc Common Stock's major shareholders?

ANI Pharmaceuticals Inc Common Stock's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.05%), Dimensional Fund Advisors LP (3.99%), LSV Asset Management (2.61%), Northern Trust Corp (0.96%), Allianz Asset Management GmbH (0.72%) and Cortina Asset Management LLC (0.71%). Company insiders that own ANI Pharmaceuticals Inc Common Stock stock include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals Inc Common Stock.

Which institutional investors are selling ANI Pharmaceuticals Inc Common Stock stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Allianz Asset Management GmbH, ETRADE Capital Management LLC, Chicago Equity Partners LLC, Schwab Charles Investment Management Inc., Northern Trust Corp, American International Group Inc. and Piermont Capital Management Inc.. Company insiders that have sold ANI Pharmaceuticals Inc Common Stock company stock in the last year include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Insider Buying and Selling for ANI Pharmaceuticals Inc Common Stock.

Which institutional investors are buying ANI Pharmaceuticals Inc Common Stock stock?

ANIP stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Millennium Management LLC, Matarin Capital Management LLC, Mackay Shields LLC, A.R.T. Advisors LLC, BlackRock Inc., Argent Capital Management LLC and Cubist Systematic Strategies LLC. View Insider Buying and Selling for ANI Pharmaceuticals Inc Common Stock.

How do I buy shares of ANI Pharmaceuticals Inc Common Stock?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals Inc Common Stock's stock price today?

One share of ANIP stock can currently be purchased for approximately $61.68.

How big of a company is ANI Pharmaceuticals Inc Common Stock?

ANI Pharmaceuticals Inc Common Stock has a market capitalization of $760.02 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals Inc Common Stock employs 173 workers across the globe.

How can I contact ANI Pharmaceuticals Inc Common Stock?

ANI Pharmaceuticals Inc Common Stock's mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]


MarketBeat Community Rating for ANI Pharmaceuticals Inc Common Stock (ANIP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals Inc Common Stock and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for ANI Pharmaceuticals Inc Common Stock in the last 12 months. Their average twelve-month price target is $81.00, suggesting that the stock has a possible upside of 31.32%. The high price target for ANIP is $82.00 and the low price target for ANIP is $80.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $81.00$72.6667$71.00$67.3333
Price Target Upside: 31.32% upside20.31% upside11.62% upside12.02% upside

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Consensus Price Target History

Price Target History for ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP)

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Canaccord GenuitySet Price TargetBuy$82.00HighView Rating Details
7/4/2017GuggenheimReiterated RatingBuy$80.00LowView Rating Details
5/6/2017Roth CapitalSet Price TargetHold$56.00LowView Rating Details
8/5/2016OppenheimerBoost Price TargetOutperform$65.00 ➝ $71.00N/AView Rating Details
7/19/2016CitigroupUpgradeOutperform$65.00N/AView Rating Details
6/22/2016Raymond JamesInitiated CoverageStrong-Buy$68.00N/AView Rating Details
5/24/2016Standpoint ResearchDowngradeBuy ➝ HoldN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Earnings History and Estimates Chart

Earnings by Quarter for ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP)

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Earnings Estimates

Current Year EPS Consensus Estimate: $5.43 EPS
Next Year EPS Consensus Estimate: $5.5 EPS

ANI Pharmaceuticals Inc Common Stock (NASDAQ ANIP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018$1.28$1.32$49.93 million$46.48 millionViewN/AView Earnings Details
2/27/2018Q4 17$1.02$1.08$52.55 million$47.30 millionViewN/AView Earnings Details
11/2/2017Q3 2017$0.99$1.11$48.12 million$48.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.79$0.98$43.20 million$44.80 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.70$0.74$39.63 million$36.60 millionViewListenView Earnings Details
3/2/2017Q4 2016$1.09$0.84$40.98 million$38.20 millionViewListenView Earnings Details
11/3/2016Q316$1.08$1.09$34.34 million$38.53 millionViewN/AView Earnings Details
8/4/2016Q216$0.77$1.11$27.63 million$31.30 millionViewN/AView Earnings Details
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details
5/5/2015Q115$0.56$0.53$19.86 million$18.80 millionViewN/AView Earnings Details
2/19/2015Q414$0.57$0.60$17.98 million$21.04 millionViewN/AView Earnings Details
11/3/2014Q314$0.43$0.59$14.60 million$17.40 millionViewN/AView Earnings Details
8/4/2014Q214($0.01)($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details
2/18/2014Q4 2013$0.23$0.35$9.18 million$10.53 millionViewN/AView Earnings Details
11/7/2013$0.16$7.84 millionViewN/AView Earnings Details
8/9/2013Q2 2013($1.26)$6.15 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.54)ViewN/AView Earnings Details
3/1/2013Q4 2012($0.96)ViewN/AView Earnings Details
11/8/2012Q312($0.36)($0.27)ViewN/AView Earnings Details
8/1/2012Q2 2012($2.46)($2.18)ViewN/AView Earnings Details
5/8/2012Q1 2012($2.52)($3.24)ViewN/AView Earnings Details
3/13/2012Q4 2011($3.96)($2.16)ViewN/AView Earnings Details
11/9/2011Q3 2011($5.04)($4.39)ViewN/AView Earnings Details
7/25/2011Q2 2011($6.48)($5.76)ViewN/AView Earnings Details
5/10/2011Q1 2011($5.40)($7.20)ViewN/AView Earnings Details
3/16/2011Q4 2010($5.40)($6.48)ViewN/AView Earnings Details
11/12/2010Q3 2010($5.04)($5.76)ViewN/AView Earnings Details
8/12/2010Q2 2010($3.96)($6.12)ViewN/AView Earnings Details
5/14/2010Q1 2010($3.96)($6.84)ViewN/AView Earnings Details
11/9/2009Q3 2009($5.76)($5.79)ViewN/AView Earnings Details
8/7/2009Q2 2009($5.40)($6.12)ViewN/AView Earnings Details
5/11/2009Q1 2009($5.76)($5.40)ViewN/AView Earnings Details
3/16/2009Q4 2008($8.64)($1.80)ViewN/AView Earnings Details
11/10/2008Q3 2008($7.20)($8.64)ViewN/AView Earnings Details
8/11/2008Q2 2008($5.40)($7.92)ViewN/AView Earnings Details
5/9/2008Q1 2008($4.32)($4.68)ViewN/AView Earnings Details
3/17/2008Q4 2007($2.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ANI Pharmaceuticals Inc Common Stock (NASDAQ ANIP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.10%
Institutional Ownership Percentage: 61.35%
Insider Trading History for ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP)
Insider Trading History for ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP)

ANI Pharmaceuticals Inc Common Stock (NASDAQ ANIP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Tracy MarshbanksDirectorSell38,236$62.33$2,383,249.88View SEC Filing  
5/10/2018Tracy MarshbanksDirectorSell62,431$62.07$3,875,092.17View SEC Filing  
4/18/2018Tracy MarshbanksDirectorSell33,200$62.09$2,061,388.00View SEC Filing  
3/19/2018Daniel RaynorDirectorSell7,215$60.85$439,032.75View SEC Filing  
3/14/2018Arthur PrzybylInsiderSell40,000$61.83$2,473,200.00225,706View SEC Filing  
3/14/2018Daniel RaynorDirectorSell27,964$62.24$1,740,479.36View SEC Filing  
3/12/2018Tracy MarshbanksDirectorSell64,221$63.03$4,047,849.63View SEC Filing  
3/8/2018Tracy MarshbanksDirectorSell15,391$63.08$970,864.28View SEC Filing  
3/5/2018James G MarkenSVPSell4,177$61.92$258,639.8466,439View SEC Filing  
3/1/2018Robert W SchrepferSVPSell28,652$61.66$1,766,682.3241,590View SEC Filing  
8/22/2016Arthur PrzybylInsiderSell37,455$66.97$2,508,361.35200,788View SEC Filing  
8/8/2016Robert W SchrepferVPSell12,500$67.06$838,250.0017,362View SEC Filing  
12/18/2015James G MarkenVPSell3,500$43.26$151,410.0045,983View SEC Filing  
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00145,195View SEC Filing  
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.0023,914View SEC Filing  
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ANI Pharmaceuticals Inc Common Stock (NASDAQ ANIP) News Headlines

Source:
DateHeadline
Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?
finance.yahoo.com - May 21 at 4:45 PM
ANI Pharmaceuticals, Inc. (ANIP) Director Sells $2,383,249.88 in StockANI Pharmaceuticals, Inc. (ANIP) Director Sells $2,383,249.88 in Stock
www.americanbankingnews.com - May 16 at 7:17 PM
Form 8-K ANI PHARMACEUTICALS INC For: May 16Form 8-K ANI PHARMACEUTICALS INC For: May 16
www.streetinsider.com - May 16 at 4:56 PM
What Does ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Share Price Indicate?What Does ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Share Price Indicate?
finance.yahoo.com - May 15 at 5:14 PM
Zacks Investment Research Upgrades ANI Pharmaceuticals (ANIP) to "Buy"Zacks Investment Research Upgrades ANI Pharmaceuticals (ANIP) to "Buy"
www.americanbankingnews.com - May 14 at 5:24 PM
ANI Pharmaceuticals (ANIP) Lifted to "Hold" at BidaskClubANI Pharmaceuticals (ANIP) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - May 11 at 9:17 PM
ANI Pharmaceuticals, Inc. (ANIP) Director Sells $3,875,092.17 in StockANI Pharmaceuticals, Inc. (ANIP) Director Sells $3,875,092.17 in Stock
www.americanbankingnews.com - May 11 at 7:25 PM
Edited Transcript of ANIP earnings conference call or presentation 8-May-18 2:30pm GMTEdited Transcript of ANIP earnings conference call or presentation 8-May-18 2:30pm GMT
finance.yahoo.com - May 10 at 9:08 AM
ANI Pharmaceuticals (ANIP) Given a $82.00 Price Target by Canaccord Genuity AnalystsANI Pharmaceuticals (ANIP) Given a $82.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - May 9 at 12:08 PM
ANI Pharmaceuticals (ANIP) CEO Arthur Przybyl on Q1 2018 Results - Earnings Call TranscriptANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:03 AM
ANI Pharmaceuticals beats by $0.04, misses on revenueANI Pharmaceuticals beats by $0.04, misses on revenue
seekingalpha.com - May 8 at 4:55 PM
ANI: 1Q Earnings SnapshotANI: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 4:55 PM
ANI Pharmaceuticals (ANIP) Posts  Earnings Results, Beats Estimates By $0.04 EPSANI Pharmaceuticals (ANIP) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 8 at 12:13 PM
ANI Pharmaceuticals, Inc. Q1 adjusted earnings Beat EstimatesANI Pharmaceuticals, Inc. Q1 adjusted earnings Beat Estimates
www.nasdaq.com - May 8 at 8:57 AM
ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms GuidanceANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance
finance.yahoo.com - May 8 at 8:57 AM
ANI Pharmaceuticals (ANIP) Releases FY18 Earnings GuidanceANI Pharmaceuticals (ANIP) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 8:56 AM
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/ImpaxANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
finance.yahoo.com - May 7 at 8:54 AM
ANI Pharmaceuticals (ANIP) to Release Quarterly Earnings on TuesdayANI Pharmaceuticals (ANIP) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 2 at 8:47 PM
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial ResultsANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results
finance.yahoo.com - May 1 at 9:03 AM
ANI Pharmaceuticals, Inc. (ANIP) Receives Average Recommendation of "Hold" from BrokeragesANI Pharmaceuticals, Inc. (ANIP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 29 at 1:34 AM
BidaskClub Lowers ANI Pharmaceuticals (ANIP) to SellBidaskClub Lowers ANI Pharmaceuticals (ANIP) to Sell
www.americanbankingnews.com - April 25 at 12:58 AM
ANI Pharmaceuticals (ANIP) Earns Buy Rating from GuggenheimANI Pharmaceuticals (ANIP) Earns Buy Rating from Guggenheim
www.americanbankingnews.com - April 19 at 11:52 PM
Tracy Marshbanks Sells 33,200 Shares of ANI Pharmaceuticals, Inc. (ANIP) StockTracy Marshbanks Sells 33,200 Shares of ANI Pharmaceuticals, Inc. (ANIP) Stock
www.americanbankingnews.com - April 19 at 7:20 PM
FDA OKs ANI Pharmas generic morphine oral solutionFDA OKs ANI Pharma's generic morphine oral solution
seekingalpha.com - April 18 at 5:07 PM
BRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral SolutionBRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution
www.reuters.com - April 18 at 9:01 AM
ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral SolutionANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
finance.yahoo.com - April 18 at 9:01 AM
ANI Pharmaceuticals (ANIP) Now Covered by Analysts at Canaccord GenuityANI Pharmaceuticals (ANIP) Now Covered by Analysts at Canaccord Genuity
www.americanbankingnews.com - April 15 at 9:45 AM
ANI Pharmaceuticals (ANIP) Rating Increased to Hold at BidaskClubANI Pharmaceuticals (ANIP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 12 at 10:47 AM
ANI Pharmaceuticals (ANIP) Given Buy Rating at Canaccord GenuityANI Pharmaceuticals (ANIP) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - April 7 at 12:31 PM
ANI Pharma (ANIP) Buys 23 ANDAs from IDT Australia, Ltd.ANI Pharma (ANIP) Buys 23 ANDAs from IDT Australia, Ltd.
www.streetinsider.com - April 4 at 3:39 PM
ANI Acquires 23 ANDAs from IDT Australia, Ltd.ANI Acquires 23 ANDAs from IDT Australia, Ltd.
finance.yahoo.com - April 4 at 9:04 AM
ANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by AnalystsANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 1:40 AM
ANI Pharmaceuticals (ANIP) Downgraded to "Hold" at ValuEngineANI Pharmaceuticals (ANIP) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 7:34 PM
Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) A Financially Sound Company?Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) A Financially Sound Company?
finance.yahoo.com - April 3 at 4:54 PM
ANI Pharmaceuticals (ANIP) Downgraded to Hold at BidaskClubANI Pharmaceuticals (ANIP) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM
Canaccord Genuity Analysts Give ANI Pharmaceuticals (ANIP) a $82.00 Price TargetCanaccord Genuity Analysts Give ANI Pharmaceuticals (ANIP) a $82.00 Price Target
www.americanbankingnews.com - March 24 at 5:43 PM
ANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 7,215 SharesANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 7,215 Shares
www.americanbankingnews.com - March 19 at 7:30 PM
Where ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Earnings Growth Stands Against Its IndustryWhere ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 16 at 9:11 AM
ANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 27,964 SharesANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 27,964 Shares
www.americanbankingnews.com - March 14 at 7:11 PM
ANI Pharmaceuticals Inc (ANIP) Insider Sells $2,473,200.00 in StockANI Pharmaceuticals Inc (ANIP) Insider Sells $2,473,200.00 in Stock
www.americanbankingnews.com - March 14 at 7:10 PM
Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?
www.zacks.com - March 14 at 9:44 AM
Tracy Marshbanks Sells 15,391 Shares of ANI Pharmaceuticals Inc (ANIP) StockTracy Marshbanks Sells 15,391 Shares of ANI Pharmaceuticals Inc (ANIP) Stock
www.americanbankingnews.com - March 12 at 10:28 PM
Tracy Marshbanks Sells 64,221 Shares of ANI Pharmaceuticals Inc (ANIP) StockTracy Marshbanks Sells 64,221 Shares of ANI Pharmaceuticals Inc (ANIP) Stock
www.americanbankingnews.com - March 12 at 10:28 PM
ANI Pharmaceuticals Inc (ANIP) Given Consensus Rating of "Hold" by BrokeragesANI Pharmaceuticals Inc (ANIP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 1:28 AM
Wired News – Aptose Biosciences Inked Exclusive License Agreement with OHM Oncology for APL-581Wired News – Aptose Biosciences Inked Exclusive License Agreement with OHM Oncology for APL-581
finance.yahoo.com - March 9 at 9:22 AM
ANI Pharmaceuticals (ANIP) Presents At Raymond James 39th Annual Institutional Investors Conference - SlideshowANI Pharmaceuticals (ANIP) Presents At Raymond James 39th Annual Institutional Investors Conference - Slideshow
seekingalpha.com - March 8 at 5:52 PM
Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 4,177 Shares of StockInsider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 4,177 Shares of Stock
www.americanbankingnews.com - March 7 at 6:50 PM
ANI Pharmaceuticals Inc (ANIP) Holdings Increased by Ranger Investment Management L.P.ANI Pharmaceuticals Inc (ANIP) Holdings Increased by Ranger Investment Management L.P.
www.americanbankingnews.com - March 6 at 2:11 PM
Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 28,652 Shares of StockInsider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 28,652 Shares of Stock
www.americanbankingnews.com - March 5 at 6:22 PM
ANI Pharmaceuticals (ANIP) Stock Rating Upgraded by ValuEngineANI Pharmaceuticals (ANIP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 3 at 6:07 PM

SEC Filings

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ANI Pharmaceuticals Inc Common Stock (NASDAQ ANIP) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.